[Medicine heaven and earth] new regulations for deduction of medical insurance quota have been issued to support more traditional Chinese medicine preparations to enter the medical insurance; 66 drugs have been abandoned, 107 drugs have been reduced; Huahai, Beida, Hengrui new trends

Highlights: five departments jointly issue documents, the hospital purchase volume is insufficient, the total amount of medical insurance to be deducted should be implemented in many places, and the policy of supporting traditional Chinese medicine preparation to enter the medical insurance Jiangxi 66 drug abandoned, 107 drug price reduction local government issued a new policy - Shanghai five departments jointly issue documents, the hospital purchase volume is insufficient, the total amount of medical insurance to be deducted On August 20, Shanghai Municipal Bureau of human resources and social security, Shanghai medical insurance office, Shanghai Health and Family Planning Commission, Shanghai food and drug administration, and Shanghai Price Bureau jointly issued a document announcing the launch of the third batch of medical insurance drugs with volume procurement Compared with the document issued in 2015, the volume procurement rules put more emphasis on "ensuring the quantity of the winning varieties in the volume procurement", and made it clear that "the municipal medical insurance department will deduct the corresponding amount of medical insurance expenses according to the situation for the hospitals that cannot normally complete the procurement volume" In addition, this work also requires that the bid winning varieties shall be purchased from the pharmaceutical trading or distribution enterprises designated by the bid winning enterprises through volume procurement, and any form of "second price negotiation" is strictly prohibited On August 17, the general office of Chengdu Municipal People's government issued the notice on several measures for further reform and improvement of drug production, circulation and use policies in Chengdu The announcement clearly pointed out that we should improve the efficacy of generic drugs and support the payment of traditional Chinese medicine into medical insurance Prior to this, there have been many relevant policies to support the introduction of traditional Chinese medicine into medical insurance Since July 1 this year, Jiangxi Province has incorporated 277 kinds of hospital internal preparations into the medical insurance and reimbursed them according to class A, 120 of which are traditional Chinese medicine preparations; from May 1, Zhengzhou basic medical insurance insured patients will further reduce the burden of using traditional Chinese medicine treatment, 142 kinds of therapeutic hospital traditional Chinese medicine preparations will be included in the catalogue management of Zhengzhou basic medical insurance; Hebei Province has implemented "Hebei Province central" since January 1, 2018 The regulations on medicine also requires human resources and social security departments at or above the county level to include eligible TCM diagnosis and treatment projects, Chinese herbal pieces, Chinese patent medicines and traditional Chinese medicine preparations of medical institutions into the scope of payment of basic medical insurance funds 3 Liaoning Province issued a document, with consistency evaluation reaching 3 enterprises, and the same type of drugs that failed to pass will no longer be purchased Recently, the office of Liaoning Provincial People's government issued the implementation opinions of General Office of Liaoning Provincial People's Government on reforming and improving the supply guarantee and use policy of generic drugs It is pointed out in the announcement that for more than three manufacturers of the same kind of drugs that have passed the quality and efficacy consistency evaluation of generic drugs, the drugs that have not passed the quality and efficacy consistency evaluation of generic drugs will not be used in the centralized purchase of drugs; for other drugs that have not passed the quality and efficacy consistency evaluation of generic drugs, the principles are as follows The qualification of online purchase is suspended; those who do not purchase online on the drug centralized purchase platform of Liaoning Province are not included in the scope of drug centralized purchase of Liaoning Province 4 On August 23, Shanghai may become a pilot city for the first designated use of some new anti-tumor drugs, and the pre exhibition supply and demand docking meeting for exhibitors in the exhibition area of medical devices and medical health care will be held in Shanghai On the same day, food and drug supervision, health and customs departments also carried out policy lectures on the spot Zhou Qun, chief engineer of Shanghai food and drug administration, introduced that the new policies being implemented include the provisions related to medicine and health care products in the action plan for Shanghai to implement the major national measures to further expand the opening up and accelerate the establishment of a new open economic system recently published Among them, the policy of using the new anti-tumor drugs which have been listed overseas urgently in Shanghai is also being implemented In the first half of the year, the operating revenue of Huahai Pharmaceutical Co., Ltd was 2.539 billion yuan, with a net profit decrease of 22.37% According to the latest mid-2018 report released by Huahai Pharmaceutical Co., Ltd on August 25, its operating revenue was 2.54 billion yuan, with a year-on-year increase of 8.01%; the net profit attributable to shareholders of listed companies was 229 million yuan, with a year-on-year decrease of 22.37% According to the announcement, Huahai Pharmaceutical Co., Ltd has 55 preparation products with the US anda number, and 10 products (15 product specifications) have passed the domestic consistency evaluation In the first half of the year, the performance of the second saps fell in an all-round way On August 24, a number of new tonic drugs were added Saps published this year's half year report of 2018 According to the announcement, the operating revenue of saps decreased by 21.32% year on year, and the net profit decreased by 43.86% year on year Among them, the sales revenue of eye drops decreased by 43.12% year-on-year, and the sales revenue of Chinese patent medicine products from the subsidiary, Qiangshen pharmaceutical, decreased by 48.39% year-on-year The announcement also showed that in the first half of the year, the subsidiary's health medicine industry added new products such as Shiquan Dabu pill and Suoyang Gujing pill The number of mergers and acquisitions of three or four listed pharmaceutical companies in three months has reached nearly 700 large pharmacies for common people The financial report of the first quarter of 2016-2018 shows that the cumulative number of mergers and acquisitions or franchises during the period has reached 960 Among them, 347 joined in the first quarter of 2018 alone In the first quarter of 2018, the number of M & A stores of Yifeng pharmacy has caught up with that of 2017 In the half year of 2018, Yixintang has added 338 stores From January to March, dashanlin added 263 stores, including 130 self built, 133 purchased and 14 closed Sihai Nanhai Pharmaceutical Co., Ltd suspended trading for 8 months, and stopped purchasing Qili Pharmaceutical Co., Ltd In the evening of August 21, Hainan Haiyao issued the suggestive announcement on the termination of major asset restructuring, saying that in view of the recent great changes in the M & a market of the pharmaceutical industry, the company and the counterparties did not reach a final agreement on the valuation of the target company In order to effectively protect the interests of listed companies and small and medium-sized shareholders, both parties agreed to terminate the transaction At the same time, Hainan Haiyao promised not to plan any major asset restructuring matters for at least one month from the date of disclosure of the announcement on termination of this major asset restructuring Wulingkang Pharmaceutical Co., Ltd acquired tumor hospital with a revenue of 100 million yuan A few days ago, Lingkang Pharmaceutical Co., Ltd., a listed company, announced a plan to acquire part of the equity of Chengmei international medical center of Hainan Tumor Hospital, the main operating body of Boao super hospital in Hainan Province According to the plan, Lingkang pharmaceutical will purchase 25% equity of Chengmei international held by Hainan Cancer Hospital Co., Ltd with 100 million yuan in cash However, according to media reports, the operating revenue of Chengmei international in 2017 and January March 2018 was 0 6 On August 20, when Changzhou No.4 Pharmaceutical Co., Ltd spent 40 million to buy the Chinese patent for the drug under research el-3016, Enhua Pharmaceutical Co., Ltd issued a notice on signing the patent license agreement for the drug under research el-3016 between its holding subsidiary and Changzhou No.4 Pharmaceutical Co., Ltd It is understood that the total amount of the entry fee for patent rights and interests is 40 million yuan (RMB) This time, enhualuokang will exclusively license to the patent technology product under research of Changzhou No.4 pharmaceutical - antidepressants (el-3016), which only involves the Chinese market and rights and interests of el-3016, and does not affect the transfer and development of the international market and rights and interests of el-3016 Qibaida pharmaceutical promised to further reduce the price of exetinib by 3.86% Recently, Beida Pharmaceutical Co., Ltd said in a survey that with the implementation of the follow-up measures to reduce the after tax of anticancer drugs by the National Medical Security Bureau and other relevant departments, and the acceleration of the price reduction of anticancer drugs, the company actively cooperated and promised to adjust the online prices of each province of ektini at the end of July, further reducing the price by 3.86% on the basis of the national negotiation price in 2016, and the adjusted price was 1345.056 yuan / box Before September 1, 2018, the company will apply to all provincial drug bidding and purchasing departments to adjust the price of exetane online The adjusted price will be valid until December 31, 2019 Eight Hengrui obtained the clinical approval document of ins068 injection today, Hengrui released a notice that its subsidiaries Chengdu Shengdi Pharmaceutical Co., Ltd and Shanghai Hengrui Pharmaceutical Co., Ltd recently received the approval document for clinical trials of drugs approved and issued by the State Drug Administration, and will launch phase I clinical trials in the near future The drug (ins068 injection) is a long-acting insulin, which is intended to be used in the treatment of type 1 and type 2 diabetes Up to now, Hengrui has invested about 38.6 million yuan in the R & D project of the product Price rise of local drugs: on August 21, another batch of commonly used drugs rose in price, Shanghai Sunshine pharmaceutical purchase network released "the second batch of commonly used and low-cost drugs in Shanghai in 2018 were purchased on the Internet and did not publish the description of drugs" More than 30 commonly used drugs, including chlorphenamine maleate tablets, Niuhuang Jiedu Tablets and Banlangen Granules, are considered to have increased too much It is reported that more than 30 commonly used drugs are mainly from Shanxi Fenhe Pharmaceutical Co., Ltd (6 products are listed), Lanzhou foci Pharmaceutical Co., Ltd (6 products are listed), Chongqing No.2 traditional Chinese medicine plant of Taiji group, Chongqing Kerui Pharmaceutical Co., Ltd., Guangxi Tainuo Pharmaceutical Co., Ltd., and other pharmaceutical enterprises 2 Price reduction: eight provinces urged the price of anticancer drugs to fall again Heilongjiang asked for a reduction of 28 drug prices Jiangxi 66 abandoned the standard 107 drug prices dropped August 17 to August 23 Eight provinces, including Sichuan, Jiangxi, Anhui and Shanxi, have issued a notice requiring relevant enterprises to submit the application for price adjustment of anticancer drugs negotiated by the state in the early stage in time, and determined September 30 as the deadline It is understood that 12 of the 14 varieties of price reduction are the second batch of national negotiation varieties and 2 are the first batch of national negotiation varieties, all of which are anti-cancer drugs On August 23, Heilongjiang provincial drug centralized purchase network released the announcement on lowering the price of some enterprises' import product platforms The price of 28 drugs has been adjusted by 2% - 9% If the drugs requiring price adjustment belong to the bidding procurement, the medical institutions shall purchase the drugs according to the adjusted drug price, and no price negotiation shall be conducted On the same day, Jiangxi Medical purchasing service center printed and distributed the notice on adjusting the price and purchasing qualification of "two envelope" products in public bidding It is required to reduce the price of relevant products from the date of this notice; the notice stipulates that the bid winning products will directly reduce the bid price; the price limit of online products will be lowered, and if the original agreed transaction price is higher than the limit price, the agreed transaction price will be lowered to the limit level at the same time; for drugs that pass the consistency evaluation of generic drugs, the bid price and limit price will not be adjusted, and the previous adjustment will be restored; different enterprises If the Bidder intends to accept the price adjustment and submits the bid rejection application, it shall be deemed as abandoning the qualification of winning the bid (Networking) According to the announcement, 66 drugs were abandoned and 107 drugs were reduced in price Only amlodipine besylate tablets, which had been evaluated by CR SECCO for consistency, increased the price limit Information source: yaozhi.com, china.com finance and economics, sepilan, bureau of health and information, EMBA of pharmaceutical industry, local medical station, and big health headlines of listed companies, etc statement: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.